Trends in Close Margin Status and Radiation Therapy Boost in Early Stage Breast Cancer Treated with Breast Conserving Therapy

Document Type

Article

Publication Date

11-1-2020

Publication Title

International Journal of Radiation Oncology • Biology • Physics

Abstract

Purpose/Objective(s): The Society of Surgical Oncology and American Society for Radiation Oncology released a consensus statement in 2014 (later endorsed by Choosing Wisely in 2016) recommending “no tumor on ink” as an adequate margin for breast cancer treated with lumpectomy. This guideline targeted patients with close margins (CM, i.e. 2 mm or less) in order to decrease rates of re-excision, improve cosmetic outcomes, and decrease costs. We hypothesize that a consequence of this policy would be an increased rate of CM and corresponding increase in radiation therapy boost (RTB) utilization to compensate. Materials/Methods: A statewide, multi-institutional consortium of up to 26 academic and community clinics prospectively collected patient level data from 2012 e 2019 of breast cancer patients treated with breast conserving therapy. For this analysis, inclusion criteria included T0-3 disease, lumpectomy for initial surgical management, pathologic margin of 2 mm or less, and use of adjuvant radiation therapy (either conventional [CFX] or accelerated [AFX] fractionation with or without boost). Chisquare testing was used to compare time periods. Results: A total of 12,499 pts were in the database from which CM was identified in 383/2480 DCIS pts (15.4%) and 1110/10019 carcinoma pts (11.1%). Comparing pre- and post- Choosing Wisely endorsement (2012- 2016 vs. 2017-2019), rates of CM decreased for both DCIS and carcinoma (13.9% vs. 9.5%, p

Volume

108

Issue

3S

First Page

37

Last Page

38

DOI

10.1016/j.ijrobp.2020.07.1070

Link to Full Text

Share

COinS